MajesTEC-9
Phase 3 Clinical Trial Comparing a Study Medication Alone Versus Pomalidomide, Bortezomib, Dexamethasone or Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
What will happen during the trial?
This clinical trial is seeking approximately 590 patients, who will be randomly assigned into one of two different groups. You will have a 50% chance of being in either group. This study is open-label, which means that both the participants and the study team will know which group they have been placed in and which therapies they will receive. Participants may continue to participate in the study as long as their myeloma doesn’t get worse and they don’t experience bad side effects.
Group A will receive the study medication by itself. Participants in Group B will receive either Pomalidomide, Bortezomib and Dexamethasone OR Carfilzomib and Dexamethasone. The study physician will decide which combination you receive, depending on your treatment history and other factors.
The study medication used in Group A is a bispecific antibody that targets two different proteins. The two proteins are CD3 on your own T-cells, and BCMA, which is found on myeloma cells. This medication may work by bringing together your T-cells and myeloma cells in order to help your own immune system fight your myeloma.
You will not be paid for taking part in this study. You may receive reimbursement or stipend(s) to help with your expenses (e.g., mileage, parking, and/or meals) for attending study visits. If a caregiver is needed to accompany you to your study visits, your caregiver may receive reimbursement or stipend(s) to offset expenses (e.g. meals) for attending study visits with you. If applicable, travel assistance (e.g. car service, train, hotel arrangements) may be offered in lieu of reimbursement, to help you get to and from your study visits and to provide accommodations as necessary during your participation in the study. The study site will discuss the options that are available for you. Janssen is committed to Health Equity. Once assigned to a study site, please inquire about financial programs in place to support clinical trial participation.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 650 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, Randomization
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1792
- NCT Identifier
- NCT05572515
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.